Investing
AstraZeneca to buy Pfizer’s rare disease gene therapy portfolio for up to $1 billion
© Reuters. FILE PHOTO-Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
2/2
(Reuters) -AstraZeneca said on Friday its unit Alexion (NASDAQ:) has agreed to buy U.S. drugmaker Pfizer ‘s (N:) early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales.
AstraZeneca (NASDAQ:) bought Alexion in 2021. It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said.
The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on Alexion and AstraZeneca’s capabilities in genomic medicine, it said.
AAV capsids have been shown to be an effective mechanism for delivering therapeutic gene cargos for gene therapy and gene editing, the company said.
Read the full article here
-
Investing4 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income4 days ago
How to Create a Routine That Balances Rest and Business Success
-
Side Hustles5 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles2 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Side Hustles6 days ago
MIT Gives Free Tuition For Families Earning $200,000 or Less
-
Passive Income5 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Side Hustles4 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel
-
Investing1 day ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters